Connor, Clark & Lunn Investment Management Ltd. Spectrum Pharmaceuticals Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $18.8 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021
SELL
$2.15 - $3.82 $55,891 - $99,304
-25,996 Closed
0 $0
Q2 2021

Aug 12, 2021
BUY
$2.89 - $4.45 $75,128 - $115,682
25,996 New
25,996 $97,000
Q1 2021

May 13, 2021
SELL
$2.9 - $4.09 $222,560 - $313,887
-76,745 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$3.38 - $5.14 $259,398 - $394,469
76,745 New
76,745 $262,000
Q3 2020

Nov 12, 2020
SELL
$2.99 - $4.9 $765,081 - $1.25 Million
-255,880 Closed
0 $0
Q2 2020

Aug 13, 2020
SELL
$2.11 - $3.38 $185,667 - $297,419
-87,994 Reduced 25.59%
255,880 $865,000
Q1 2020

May 13, 2020
BUY
$1.83 - $3.45 $258,119 - $486,619
141,049 Added 69.54%
343,874 $801,000
Q4 2019

Feb 12, 2020
SELL
$3.5 - $10.35 $19,337 - $57,183
-5,525 Reduced 2.65%
202,825 $738,000
Q3 2019

Nov 13, 2019
BUY
$7.03 - $9.7 $219,511 - $302,882
31,225 Added 17.63%
208,350 $1.73 Million
Q2 2019

Aug 07, 2019
BUY
$7.36 - $11.26 $1.09 Million - $1.67 Million
148,575 Added 520.4%
177,125 $1.53 Million
Q1 2019

May 08, 2019
BUY
$9.08 - $11.84 $259,234 - $338,032
28,550 New
28,550 $305,000
Q4 2018

Feb 12, 2019
SELL
$6.39 - $16.99 $324,548 - $862,922
-50,790 Closed
0 $0
Q3 2018

Nov 13, 2018
BUY
$16.52 - $24.82 $839,050 - $1.26 Million
50,790 New
50,790 $853,000

Others Institutions Holding SPPI

# of Institutions
1
Shares Held
115K
Call Options Held
0
Put Options Held
0
View Full List

About SPECTRUM PHARMACEUTICALS INC

SPPI Quotes by TradingView
  • Ticker SPPI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,164,000
  • Description
  • Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...
More about SPPI
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email